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ABSTRACT
Purpose MITOsym, a new mathematical model of hepatocellu-
lar respiration and bioenergetics, has been developed in partner-
ship with the DILIsym® model with the purpose of translating
in vitro compound screening data into predictions of drug induced
liver injury (DILI) risk for patients. The combined efforts of these
two models should increase the efficiency of evaluating com-
pounds in drug development in addition to enhancing patient
care.
Methods MITOsym includes the basic, essential biochemical
pathways associated with hepatocellular respiration and bioener-
getics, includingmitochondrial oxidative phosphorylation, electron
transport chain activity, mitochondrial membrane potential, and
glycolysis; also included are dynamic feedback signals based on
perturbation of these pathways. The quantitative relationships
included in MITOsym are based primarily on published data;
additional new experiments were also performed in HepG2 cells
to determine the effects on oxygen consumption rate as media
glucose concentrations or oligomycin concentrations were varied.
The effects of varying concentrations of FCCP on the mitochon-
drial proton gradient were also measured in HepG2 cells.
Results MITOsym simulates and recapitulates the reported dy-
namic changes to hepatocellular oxygen consumption rates, ex-
tracellular acidification rates, the mitochondrial proton gradient,
and ATP concentrations in the presence of classic mitochondrial
toxins such as rotenone, FCCP, and oligomycin.
Conclusions MITOsym can be used to simulate hepatocellular
respiration and bioenergetics and provide mechanistic hypotheses
to facilitate the translation of in vitro data collection to predictions of
in vivo human hepatotoxicity risk for novel compounds.
KEY WORDS bioenergetics . extracellular acidification rate .
mechanism-based . mitochondrial toxicity . oxygen consumption
rate
INTRODUCTION
Drug-induced liver injury (DILI) is a significant issue in drug
development, both preclinically and clinically. While the inci-
dence of human DILI is relatively low (1), drugs associated with
DILI lead to substantial cost for drug developers due to mostly
late stage attrition. As such, the pharmaceutical industry and
regulatory agencies are devoting substantial resources toward
improving the preclinical and clinical screening processes. Liver
injury is known to be multifactorial with mitochondrial toxicity
being one of the known contributors. Recent advances in
mitochondrial function assays have enhanced the ability to
screen compounds for possible mitochondrial toxicity liabilities
(2–5). These include high-throughput cellular respiration mea-
surement systems such as the Seahorse Biosciences XF ana-
lyzers (6). The XF analyzer provides real time measurement of
cellular bioenergetics in whole cells. These new assay systems
provide an advantage over the classic isolated mitochondrial
respiration assays by providing an environment that more
closely replicates the native, in vivo milieu (4). These cell-based
assay systems also provide the ability to estimate oxygen con-
sumption, glycolysis flux and adaptive, compensatory changes
during periods of mitochondria duress (7).
Mechanistic mathematical models are available to assist in
evaluating compounds for hepatotoxicity liabilities. One such
example is the DILIsym®model, which provides the ability to
predict DILI based on preclinical in vitro and/or in vivo data (8).
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Mathematical models can assist in analyzing and interpreting
complex data sets, understanding mechanisms of drug action,
generating testable hypotheses, and guiding experimentation.
The information provided by the simulations can help mini-
mize experimentation, thereby saving time and effort. More-
over, simulations of ‘what if’ scenarios can provide researchers
with the ability to predict experimental outcomes and make
decisions that can improve patient safety.
This paper describes a new mechanistic, mathematical
model of hepatocellular respiration and bioenergetics, called
MITOsym. MITOsym simulates and predicts bioenergetics
in the presence or absence of compounds that modulate
mitochondrial function in HepG2 cells. The model contains
many essential bioenergetic components such as mitochondri-
al oxidative phosphorylation, electron transport chain activity,
mitochondrial membrane potential, glycolysis, and cellular
pathways for metabolic regulation of bioenergetics as illustrat-
ed in Fig. 1. The effector compounds have been chosen for
their well-characterized effects on different aspects of
mitochondria function; rotenone is an inhibitor of com-
plex I of the electron transport chain, oligomycin is an
inhibitor of the F1F0 ATPase, and FCCP uncouples the
mitochondria proton gradient. Characterizing the dis-
ruption of each of these processes with these compounds
has elucidated quantitation of key feedback signals with-
in and beyond mitochondria. The model has been de-
signed and calibrated with a variety of data, much of it
collected using the Seahorse Biosciences XF analyzer.
While considerable amounts of the data that were used
to construct the model were publically available in the
literature, we also conducted additional experiments to
generate specific sets of data; these data are described
in this report as well.
MITOsym has also been designed to provide inputs into
DILIsym® and facilitate the prediction of in vivo hepatotoxic-
ity based on in vitro compound data. DILIsym® and
MITOsym software are developed under the DILI-sim Initia-
tive, a pre-competitive partnership between the Hamner-
UNC Institute for Drug Safety Sciences and 14 pharmaceu-
tical companies. For more information on access to
MITOsym and DILIsym®, see www.dilisym.com. This
simulation partnership should increase the efficiency and
effectiveness of evaluating the potential for new compounds
with mitochondria liabilities to elicit DILI.
MATERIALS AND METHODS
Materials
All chemicals were purchased from Sigma-Aldrich (St. Louis,
MO) and were of the highest purity available. The fluores-
cence dyes, tetramethylrhodamine methyl ester (TMRM) and
Hoechst 33342, were from Invitrogen (Carlsbad, CA). Cell
culture media and supplements were from Invitrogen (Carls-
bad, CA). Low-buffered RPMI medium was from Molecular
Devices (Sunnyvale, CA). XF96 sensor cartridges and XF96-
well plates were from Seahorse Bioscience (Billerica, MA).
Fig. 1 Schematic diagram of MITOsym: MITOsym includes key biochemical processes for cellular and mitochondrial bioenergetic responses. Classic effectors
(oligomycin, FCCP and rotenone) were used to investigate mechanism-specific mitochondrial toxicity. Cellular feedback signals were used to maintain
mitochondrial homeostasis or modulate mitochondrial response to external stressors. Primary model outputs include oxygen consumption rate (OCR),
extracellular acidification rate (ECAR) and ATP. State variables in MITOsym are displayed as white rectangles, while fluxes are shown in black diamonds. Feedback
signals are denoted by dashed lines. Descriptions of the equations describing the state variables, fluxes, and feedback signals are given in Tables II, III and IV and
Appendix B.
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Cell Culture Conditions for HepG2 Cells
HepG2 cells were obtained from the American Type Culture
Collection (Manassas, VA). Cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen 11885–084)
containing 5.5 mM glucose and 1 mM sodium pyruvate and
supplemented with 10% fetal bovine serum, 5 mM 4-(2-
hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES),
and 100 units/mL penicillin-streptomycin in a 37°C, 5%
CO2 humidified atmosphere.
Experimental Protocol 1: Measurement of the Effect
of FCCP on the Mitochondrial Membrane Potential
of HepG2 Cells
Mitochondrial membrane potential was measured based on
the accumulation of TMRM. HepG2 cells were seeded in 96-
well plates at 10,000 cells/well in culture medium and incu-
bated overnight in a humidified 37°C, 5% CO2 atmosphere.
The following day, cells were incubated with carbonyl cyanide
4-(trifluoromethoxy) phenylhydrazone (FCCP) at various con-
centrations in culture medium for 1 h at 37°C, 5% CO2.
TMRM and Hoechst 33342 were then added to each well
(at a final concentration of 100 nM and 4 μg/ml, respectively)
and the cells incubated at 37°C, 5%CO2 for 30min. The cells
were rinsed three times with Hanks Balanced Salt Solution
(HBSS; 200 μl/well); the final HBSS rinse was not aspirated.
Automated live-cell image acquisition was performed on a
Thermo Fisher Scientific Cellomics® ArrayScan® VTI High
Content Screening Reader using a 10X objective. An XF93-
Hoechst filter and an XF93-TRITC filter were used to image
Hoechst 33342 and TMRM, respectively. Image acquisition
was set to a minimum of 500 objects per well. Image analysis
was done using the Compartmental Analysis Bioapplication
(Thermo Fisher Scientific). Mitochondrial membrane poten-
tial staining due to TMRMwas defined as the punctate signal
around the Hoechst-stained nucleii. Raw data were exported
from vHCSView (Thermo Fisher Scientific), and IC50 values
were generated using GraphPad Prism 5 (San Diego, CA)
with non-linear regression analysis.
Experimental Protocol 2: Measurement of the Oxygen
Consumption Rate and Extracellular Acidification Rate
of HepG2 Cells in Media Containing Different Glucose
Concentrations
Oxygen consumption rates (OCR) and the extracellular acid-
ification rates (ECAR) of HepG2 cells were measured in real-
time, simultaneously, in an XF96 Extracellular Flux Analyzer
(Seahorse Bioscience, Billerica, MA) essentially as described in
Nadanaciva et al. (3) with some modifications. Cells were
seeded in XF96-well plates at 24,000 cells/80 μL culture
medium/well and incubated in a 37°C, 5% CO2 humidified
atmosphere for 24 h.
To measure the effect of various concentrations of glucose
on theOCR, ECAR, and respiratory capacity of HepG2 cells,
the culture medium from the XF96 cell plates was aspirated
the day after seeding the cells, and the cells rinsed three times
in pre-warmed assay buffer (111 mM NaCl, 4.7 mM KCl,
2 mM MgSO4, 1.2 mM Na2HPO4), pH 7.4. The cells were
then maintained in 150 μL/well assay buffer supplemented
with various concentrations of glucose at 37°C in a non-CO2
incubator for 60 min.
This cellular environment, including media glucose of
5.5 mM but excluding any mitochondrial effector drugs, is
used as the basal condition in all MITOsym simulations.
To measure the reserve capacity of the cells, FCCP
was diluted to 21 μM in assay buffer, and 25 μL pre-
loaded into reagent delivery port A of each well in the
XF96 sensor cartridge. After a 25 min calibration of the
XF96 sensor cartridge, four measurements of the OCR
and ECAR of the cells were made using a 2 min mix,
5 min measure cycle. FCCP was then injected and six
OCR and ECAR measurements were made (the final
concentration of FCCP in each well was 3 μM). The
OCR and ECAR immediately prior to FCCP injection
were used as the basal OCR and ECAR, respectively.
The first OCR and ECAR obtained after FCCP injec-
tion were used to determine the reserve capacity, i.e. the
percentage change in OCR and ECAR caused by
FCCP.
Experimental Protocol 3: The effect of Oligomycin
on OCR and ECAR
To examine the effect of oligomycin on the OCR and ECAR
of HepG2 cells, cells were seeded in XF96-well plates and the
culture mediumwas aspirated after 24 h. The cells were rinsed
three times in pre-warmed serum-free low-buffered RPMI
medium, pH 7.4. The cells were then maintained in
150 μL/well of serum-free low-buffered RPMI medium at
37°C in a non-CO2 incubator for 60 min. A compound plate
containing oligomycin at various concentrations in serum-free
low-buffered RPMI medium supplemented with 1% (v/v)
DMSO was prepared. OCR and ECAR measurements were
collected before and after addition of oligomycin as described
in Experimental protocol 2 (above). The OCR and
ECAR immediately prior to the oligomycin/vehicle in-
jection were used as the basal OCR and ECAR, re-
spectively, and were defined as 100% when generating
the oligomycin concentration response curves. The first
OCR and ECAR obtained after oligomycin injection
were used to determine the percentage change in
OCR and ECAR caused by the compound.
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Additional Data from Published Literature
Data from Nadanaciva et al. (3) were used to examine the
effects of increasing concentrations of rotenone and FCCP on
OCR and ECAR of HepG2 cells, as measured with an XF96
Analyzer. Data from more complex protocols were also in-
cluded from other publications (9–11); OCR was measured
using an XF24 analyzer during and after the serial adminis-
tration of 1 uM oligomycin, 1 uM FCCP, and 1 uM rotenone
toHepG2 cells. These data were used to support themodeling
efforts by providing quantitative information about dynamic,
cellular adaptation.
Data from a study by Marroquin et al. (2) were also includ-
ed to help characterize the relative contributions from mito-
chondria and glycolysis to total cellular ATP production. The
study included measurement of ATP at varying concentra-
tions of oligomycin, FCCP, and rotenone in HepG2 cells
cultured with 25 mM glucose or 10 mM galactose as the
primary oxidative substrate in the media. Cells cultured in
media containing galactose are unable to generate net ATP
from glycolysis and thus rely on their mitochondria for ATP
productions. Cellular ATP content was measured after 24 h of
incubation with each compound. These data were used to
support the modeling efforts by providing quantitative infor-
mation about the dynamic interplay between mitochondria
and glycolytic ATP production. Table I summarizes the time-
series and dose–response data used to optimize the changes in
cellular bioenergetics and/or respiration (relative to basal) in
response to the culture conditions and exemplar compounds
(rotenone, FCCP and oligomycin) for HepG2 cells.
Computational Modeling of Bioenergetics
Metabolic Description. A mechanism-based, computational
model, MITOsym, was developed to describe hepatocellular
bioenergetics in hepatocytes in basal conditions and when
exposed to compounds that modulate mitochondrial function.
MITOsym is seated in the MATLAB computing platform
(The MathWorks, Natick, MA) and is composed of ordinary
differential equations, algebraic expressions, and a corre-
sponding graphical user interface. MITOsym includes math-
ematical descriptions of many of the essential biochemical
components of bioenergetics, as illustrated in Fig. 1. Two
energy-generating pathways, glycolysis and mitochondrial ox-
idative phosphorylation (OXPHOS) were included. Glycoly-
sis supports cellular bioenergetics in MITOsym by directly
supplying extra-mitochondrial ATP in addition to providing
substrates for mitochondrial electron transport chain activity
(ETC) activity and ATP production (12). For mitochondrial
OXPHOS, similar to the approaches described in Hafner
et al. (13) and Ainscow et al. (14), the membrane potential
was used as an intermediate control point which was support-
ed by ETC activity and dispatched via ATP synthesis and
uncoupling. This design is in agreement with observations of
decreased proton gradient and ATP levels in isolated
mitochondria or hepatocytes treated with complex I/II inhib-
itors (15,16) or uncouplers (15).
We have simplified some aspects of cellular and mitochondri-
al biochemistry in an effort to reduce the complexity and number
of equations in MITOsym. The focus of our model is to capture
key aspects of mitochondria within the whole cell context. This
allows us to incorporate key intracellular feedback signals that
have direct and indirect effects on mitochondrial function (e.g.,
increased glycolysis in response to compromised mitochondrial
function).Within this cellular context, however, certain aspects of
mitochondrial biochemistry are not experimentally measured
such as mitochondria pH and mitochondrial ion transport.
While other models have focused on isolated mitochondria and
include these specific components, the cellular focus of
MITOsym has precluded explicitly including them.
NADH and the components of the tricarboxylic acid cycle
(aka Krebs cycle) have not been explicitly included into
MITOsym. In most cell culture conditions, the media pro-
vides ample substrate to maintain the levels of TCA interme-
diates and support ETC flux; anapleurosis is not limiting.
Moreover, compounds with hepatotoxicity liabilities have by
and large not included TCA cycle inhibition as a mechanism.
The production and utilization of NADH is not explicitly
represented in MITOsym, but its dynamics are somewhat
represented by the utilization of pyruvate. We have includ-
ed a mitochondrial pyruvate state variable upon which
ETC flux is dependent. While mitochondrial pyruvate
levels are quite low, this state variable also represents the
dynamics of mitochondrial NADH turnover. Thus specific
Table I Summary of the Experimental Data Used to Describe the Bioenergetic Responses to Various Mitochondrial Effectors in HepG2 Cell
Glucose FCCP Rotenone Oligomycin Multiple drug
OCR Measured Nadanaciva et al. (2012) Nadanaciva et al. (2012) Measured Felser et al. (2013), Zahno et al. (2011)
and Mullen et al. (2011)
Gradient Measured
ECAR Measured Nadanaciva et al. (2012) Nadanaciva et al. (2012) Measured
ATP Marroquin et al. (2007) Marroquin et al. (2007) Marroquin et al. (2007)
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disruptions in NAHD/NAD ratios (i.e., redox state) can be
represented by introducing changes in pyruvate oxidation
in MITOsym.
The details of each section of MITOsym are described below.
1) Glycolysis
a) Glycolysis is an anaerobic pathway that converts glucose
into pyruvate and generates ATP in the cytosol (17). The
glycolysis pathway is primarily represented by the dynam-
ic changes in the intermediates, glucose-6 phosphate and
pyruvate, as illustrated in Fig. 1 and as described in more
detail as follows. Glucose uptake and glucose-6-phosphate
(G6P) production:
Components comprising glucose uptake, and glucose-6-
phosphate (G6P) production were modeled using differential
equations (see, Table II, s1 through s5).
In vitro, hepatocytes take up glucose from culture media and
subject it to phosphorylation, generating glucose 6-phosphate
(G6P). G6P has numerous possible fates, including being
catabolized into pyruvate via glycolysis, or stored as glycogen.
Each of these components and processes is described in the
mathematical equations of the model for simulating mito-
chondrial function. It is assumed that the glucose concentra-
tion in the hepatocyte was in equilibrium with the media
glucose concentration. Moreover, the media glucose concen-
tration was assumed to be constant throughout each experi-
ment and simulation. Glucose uptake and phosphorylation
was modeled as a saturable process. The metabolic flux of
G6P (Fluxprod
G6P) is estimated under steady-state conditions from
flux balance analysis (Appendix A; Table III). The Km
(Michaelis-Menten constant) of G6P production is estimated
by manually adjusting the parameter value to fit the basal and
maximum respiratory dose–response data collected for vari-
ous glucose concentrations. The estimated value of Fluxprod
G6P is
1.875mM/min where synthesis of G6P is a saturable response
with Km in HepG2 cells set to 10 mM, based on Km of
glucokinase reported in vivo (18). In the model, the basal
hepatocyte G6P concentration was set to 1 mM (18).
Glycogen also participates in G6P flux in vivo, providing G6P
during fasting periods and storing G6P in the fed state. In vitro,
however, there is very little glycogen in HepG2 cells (19). There-
fore, the glycogen concentration is set to 0.001 mM and the net
G6P production from glycogen breakdown is zero in the model.
b) Pyruvate production: Pyruvate is primarily generated
from G6P when HepG2 cells are cultured in media
excluding lactate. The breakdown of each G6P molecule
generates two pyruvate molecules in addition to two (net)
ATPmolecules. The estimated basal value of Fluxprod, cellular
pyr
is 3.75 mM/min where the generation of hepatic pyru-
vate from G6P is assumed to be near maximal with Km
set to 0.01 mM and the cytosolic pyruvate concentration
is set to 5 mM.
c) ECAR computation: Lactate is a primary product of
pyruvate metabolism. As such, it is representative of gly-
colysis rates; extracellular acidification rates (ECAR) can
be used as an indicator of lactate release and glycolysis (6).
In our model, the simulated pyruvate-to-lactate metabolic
flux is used to compute the ECAR. The basal lactate flux
(Fluxprod
lac ) is estimated as 3.15 mM/min given the reported
basal ECAR is 66.2 mpH/min (3), the conversion factor is
4.28 pmoleH
þ
mpH (20), and cell volume is 9e
−8 L for 24,000 cell
(21). The mathematical equations and data used to define
the stoichiometric relationship among metabolic flux are
detailed in Appendix A (Intermediate fluxes #1) and
Table II.
2) ATP Production (Cytosol and Mitochondria)
Glycolysis supports cellular bioenergetics by directly sup-
plying extra-mitochondrial ATP and providing substrates for
Table II Metabolic Reactions and the Basal Steady State Values Computed for State Variables. See Appendix B for More MITOsym®equation Descriptions
State variable Differential equation for hepatica bioenergetics reactions Basal SS value for glucose
media
Basal SS value for galactose
media
s1 [drugcellular] d drug½ cellular
dt ¼ Fluxdruguptake−Fluxdrugcellular 0 [mM] 0 [mM]
s2 [G6P] d G6P½ 
dt ¼ Eff FluxG6Pprod −Eff Fluxpyrprod; cellular  0:5−Fluxglyprod þ Fluxglydegrad 1 [mM] 1 [mM]
s3 [Glycogen] d Glycogen½ 
dt ¼ Fluxglyprod−Fluxglydegrad 0.001 [mM] 0 [mM]
s4 [Pyruvatecellular] d Pyrcellular½ 
dt ¼ Eff Fluxpyrprod; cellular−Eff Fluxpyrprod; mito−Fluxlacprod 5 [mM] 4.7 [mM]
s5 [Pyruvatemito] d Pyr½ mito
dt ¼ Eff Fluxpyrprod; mito−Eff Fluxpyr2OXprod 5 [mM] 4.7 [mM]
s6 [OXmito] d OX½ mito
dt ¼ Eff Fluxpyr2OXprod −Eff FluxETCprod 0.3 [mM] 0.4 [mM]
s7 ΔΨm dΨmdt ¼ Conversion f  E f f F luxETCprod −E f f F luxAT Pprod;mito−Uncouplingdrug 172.2 [mM] 169.4 [mM]
s8 [ATPcellular] d AT P½ cellular
dt ¼ Eff FluxAT Pmito; lowgrad þ Eff FluxAT Pgly −k  AT P½ cellular 4 [mM] 4 [mM]
MITOsym®: A Hepatocellular Bioenergetics Model 1979
mitochondrial oxidative phosphorylation (OXPHOS) and
mitochondria ATP production. ATP production inmitochon-
dria is based on oxidative phosphorylation, the coupling of the
mitochondria proton gradient with phosphorylation of ADP
to generate ATP. The components of ATP production are
described as follows:
I. Oxidative substrate: Cytosolic pyruvate is transported into
mitochondria and then converted to acetyl-CoA by pyru-
vate dehydrogenase (17). Acetyl CoA undergoes further
oxidation through the tricarboxylic acid (TCA) cycle to
generate the ETC substrates, nicotinamide adenine dinu-
cleotide in its reduced form (NADH) and flavine adenine
dinucleotide in its reduced form (FADH2). The
MITOsym model simplifies the network of enzymes in-
volved in these processes into a two-step process, where
cytosolic pyruvate is converted to mitochondrial pyruvate
which subsequently supports ETC enzyme complex activ-
ity. In the model, mitochondrial pyruvate is a discrete state
variable that provides an intermediate pool controlling
flux through the electron transport chain. The basal con-
centration of mitochondrial pyruvate is assumed to be
equivalent to cytosolic pyruvate (e.g., for hepatocytes,
5 mM), and the basal flux of mitochondrial pyruvate
oxidation is 0.6 mM/min (detail shown in Appendix A).
The Michaelis-Menten constant (Km) is 1 mM for this
process. Mitochondrial pyruvate also serves as a regulator
for mitochondria uptake of pyruvate from cytosol in our
model as described in the cellular regulation section
(Table IV, eq. EF3).
II. Pyruvate oxidation. Pyruvate is primarily generated from
G6P when HepG2 cells are cultured in media lacking
lactate. The breakdown of each G6P molecule generates
two pyruvate molecules in addition to two (net) ATP
molecules. Pyruvate has two primary fates. It undergoes
conversion to lactate in rates proportional to the amount
of pyruvate. Mitochondrial utilization of pyruvate also
occurs via the actions of pyruvate dehydrogenase, the
tricarboxylic acid cycle enzymes, and the OXPHOS
pathway. In the basal condition for the HepG2 cells, it
was estimated that 16% of pyruvate flux (Fluxprod, cellular
pyr )
was used for mitochondrial OXPHOS. This ratio is
derived from the estimated ATP contributed from
OXPHOS and glycolysis as described in the ATP pro-
duction section, below, and in Appendix A (statement 7).
III. ETC activity and respiration: Oxygen consumption
rates (OCR) are used as an indicator of ETC activity
(4), as oxygen is consumed in the final step of the electron
transport chain. OCR in the MITOsym model is line-
arly proportional to ETC activity, (Fluxprod
ETC), which is
based on the oxidation rate of mitochondrial pyruvate
(Fluxprod
pyr2OX). The governing equations are given in
Table II, equation s6. In the basal state, ETC activity
and OCR are at 0.6 mmol/L/min and 200 pmol O2/
min, respectively. The reported OCR value is
199.6 pmoleO2/min/24000 cell (3).
IV. Proton gradient: Mitochondrial ATP synthesis is depen-
dent upon a gradient of protons (ΔΨm) that is
established as protons are pumped out of the inner
matrix into the inter-membrane space by the ETC
(4,14). The MITOsym model includes a representation
of ΔΨm (Table II, s7), computed as a state variable. The
basal steady-state ΔΨm is maintained by two opposing
processes: ETC activity leads to production of ΔΨm and
ATP synthesis dissipates it. The basal value of ΔΨm is
172 mV in MITOsym, which agrees well with the phys-
iological range of 180±40mV for isolatedmitochondria
(22).
a) Mitochondrial ATP production: Mitochondria utilize
ΔΨm to synthesize ATP via the F1FO -ATPase. The rate
Table III Metabolic Fluxes at Steady State Given Different Cell Culture Media Conditions. See Appendix B for More MITOsym®equation Descriptions
Description Glucose Galactose
F1 Fluxprod
G6P Rate of hepatocyte glucose/G6P uptake and phosphorylation,
described as a Michaelis-Menten reaction
1.875 [mM/min] 2.13[mM/min]
F2 Fluxprod, cellular
pyr Rate of hepatocyte total pyruvate production via glycolysis,
described as a Michaelis-Menten reaction
3.75 [mM/min] 4.26[mM/min]
F3 Fluxprod




pyr Rate of pyruvate use by mitochondria in absence of
effectors is linear to total pyruvate production, Fluxprod, cellular
pyr
0. 6 [mM/min] 0.84[mM/min]
F5 Fluxprod
pyr2OX Rate of pyruvate use as oxidative substrate in mitochondria,
described as a Michaelis-Menten reaction
0. 6 [mM/min] 0.84[mM/min]
F6 Fluxprod
ETC Rate of oxidative substrate used for ETC activity in mitochondria
in absence of effectors is the sum of the oxidative substrate
from mitochondrial pyruvate or fatty acid (the latter is not
included in the current model)
0. 6 [mM/min] 0.84[mM/min]
F7 Fluxprod,mito
ATP Rate of mitochondria ATP production in absence of effectors,
described as a Michaelis-Menten reaction
1000 [pmol ATP/min] 1334.7 [pmol ATP/min]
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of ATP synthesis in MITOsym is proportional to
ΔΨm. In the basal state, the mitochondrial ATP
production rate (Fluxprod,mito
ATP ) is 1000 pmol/min
(Appendix A) and the cellular ATP concentration
is 4 mM, comparable to reported in vitro data gen-
erated for this cell type (18). Reductions in ΔΨm
(e.g., via uncoupling) lead to reductions in mitochon-
drial ATP production. Also, drugs or their metabo-
lites directly inhibiting ATP synthase block H+ gra-
dient dissipation. This leads to an increase in the
simulated ΔΨm, which through a feedback manner
reduces ETC flux in MITOsym.
b) Total hepatocellular ATP production: Total hepatocellu-
lar ATP production includes ATP produced from mito-
chondria (OXPHOS) and the cytosol (glycolysis). Mito-
chondrial contributions to total cellular ATP production
for HepG2 cells are approximately 75%, with the remain-
der generated by glycolysis when cultured in 5.5 mM
glucose media . Using the basal OCR and ECAR values
for the specific cell type of interest, in this case of
199.6 pmol O2/min and 66.2 mpH/min, the fractional
contribution of ATP from OXPHOS and glycolysis was
estimated to be 1000 and 337.2 pmol ATP/min respec-
tively for HepG2 cells in MITOsym. Moreover, we esti-
mated that 16% of glycolysis flux was used for mitochon-
drial pyruvate oxidation and 84% was released as lactate
(Appendix A). This estimate was based on the presumed
glucose yield of 36 ATP during mitochondrial oxidation
and 2 ATP during glycolysis (See Appendix A for more
details). Baseline hepatocyte ATP levels in MITOsym
were based on ATP levels measured in human hepato-
cytes, and they were consistent with the reported ATP
levels in HepG2 cells.
Basal ATP turnover (production and utilization) in
MITOsym was designed to include total hepatocellular ATP
production (including mitochondria and cytosol) and first
order utilization. The steady state ATP turnover rate was
based on human caloric expenditure data, and includes
measured whole body basal metabolic rate, the fraction of
the basal metabolic rate from the liver (or organ in which the
cells of interest reside), the mass of the liver (or organ in which
the cells of interest reside), and the weighted average of the
energetic cost of synthesizing ATP from fatty acids, car-
bohydrates, and amino acids (as measured, or from
published data). Although rare, the F1FO ATPase can
reverse the direction of the typical chemical reaction
and hydrolyze ATP. In these situations, the mitochon-
dria can contribute substantially to ATP utilization.
MITOsym includes equations to account for net mito-
chondrial ATP production rates in this situation, and
the predicted ATP level can be computed both includ-
ing and excluding contributions from mitochondrial
ATP hydrolysis (see also Table IV, equation EF6-7.
The key algebraic expressions and ODE functions are
detailed in Appendix B.
3) Cellular regulation
Cells often use intracellular feedback and metabolic regu-
lation to maintain bioenergetic homeostasis. To include the
regulation of metabolic pathways in the model in response to
external stressors, pathway-specific signals were described
mathematically as a function of the relevant state variables
or intermediate products, and they were used to adjust met-
abolic fluxes as shown in Table IV. The diagram of the
regulation network including the feedback signals is shown
in Fig. 1, with descriptions of each signal given below.
a) Regulation between ΔΨm and ETC activity
A feedback signal from ΔΨm to ETC activity was included
in MITOsym based on data describing OCR changes in
hepatocytes treated with FCCP and oligomycin. As an un-
coupler, FCCP decreases the proton gradient and increases
OCR (23). Oligomycin, which inhibits the F1FO -ATPase,
increases the proton gradient and reduces OCR (22,24).
The MITOsym regulation signal based on changes in ΔΨm
Table IV Algebraic Expressions of




G6P FluxG6Pprod  SfbG6P2Glu
EF2 Eff_Fluxprod, cellular
pyr Fluxprod, cellular
pyr * SfbATP2pyr  SfbETC2pyr
EF3 Eff_Fluxprod, mito
pyr
Fluxpyrprod; mito  SfbmitoPyr
EF4 Eff_Fluxprod
pyr2OX





ATP FluxAT Pprod;mito  SfbATP2mitoATP prod DrugATPase inhibitor
EF7 Eff_Fluxmito,lowgradient
ATP Eff FluxAT Pprod;mito  1−k⋅SfbMMP2ATPð Þ
EF8 Eff_Fluxgly
ATP
Eff Fluxpyrprod; cellular  SEff glycolysis
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(S fbH Gradient ) modulates mitochondrial pyruvate utilization (Eff
_Fluxprod
pyr2OX) as shown in Table III. S fbH Gradient is described with
a non-linear Hill equation (Eq. S1):




A Hill coefficient (n=30) and Km of 165.7 mV was used to
generate a sigmoidal shape where a mild loss of gradient will
result in a steep increase of S fbH Gradient . The magnitude of this
signal was based on the FCCP data (3) where
Max S fbH Gradientð Þ
basal S fbH Gradientð Þ
=4 to allow a comparable increase in ETC activity.
b) Regulation between mitochondrial function and glycolysis
Glycolysis can increase during periods of mitochondrial
duress, as evidenced by increases in ECAR in the presence
of various mitochondrial inhibitors and uncoupling agents
(3,16). Cytosolic ATP production associated with the in-
creased glycolysis helps compensate for decreases in mito-
chondrial ATP production. Intuitively, the state of ATP bal-
ance (total ATP) would be an ideal regulator of glycolysis.
Cellular ATP/ADP ratios have been reported to regulate
glycolytic flux (25), and changes in cellular ATP concentra-
tions are used inMITOsym as a controller of glycolytic flux as
well. A second regulatory link betweenmitochondrial function
and glycolysis was included in MITOsym as well. ECAR
increases in the presence of mitochondrial inhibitors have
been observed in several reports (3,26), and a correlation has
been established between the OCR reduction and the ECAR
increase (27). As such, the relative change in ETC activity also
participates in regulating glycolysis flux. The equations for
these two regulatory signals (Eq. S2: relative change of OCR
level S fbETC2gly
 




S f bAT P2gly ¼ 1−Kð Þ
þK⋅ 2 Basal ATPtotal









c) Regulation of glucose uptake and mitochondrial pyruvate
utilization
MITOsym includes several signals where a pathway is
regulated by the intermediate of its own pathway. These
signals are used to describe the glucose uptake (S fbG6P2Glu )
and mitochondrial pyruvate utilization (S fbmitoPyr and
SfbmitoOX ). The signals, generalized as Sifb, are computed as a
Hill equation:




where signals, Sifb, are based on the basal (Sibasal) and
current (Sicurrent) states of its own intermediates.
d) Regulation of mitochondrial ATP production by ATP levels
Feedback inhibition has been reported for the mitochon-
dria F1F0 ATPase (28), whereby extant ATP levels can mod-
ulate mitochondrial ATP synthesis. The signal Sfb _
ATP2mitoATP_prod (Fig. 1) in MITOsym provides this type of
feedback on the simulatedmitochondria ATP production rate






e) ATP Regulation in glucose and galactose media
The MITOsym model has been designed to compute
cellular ATP levels when HepG2 cells are cultured in media
containing either glucose or galactose as the primary fuel
source. Galactose utilization has zero net ATP synthesized
through glycolysis (29), as the ATP produced by glycolysis is
offset by that required to phosphorylate galactose. Thus, ATP
is completely supplied by mitochondria when cells are cul-
tured in galactose. In MITOsym, the ATP production from
glycolysis is set to zero when simulating cells cultured in
galactose. A non-linear Hill equation is utilized to adjust
simulated mitochondrial ATP production. The gradient-




 n  − KmMMP2ATPð Þ
n
KmMMP2ATPn þ 1ð Þ
ðS6Þ
The Km and n parameter values in this equation were
estimated by comparing simulated cellular ATP levels with
those reported byMarroquin et al. (2). in galactose- or glucose-
cultured HepG2 cells 24 h following treatment with FCCP or
rotenone (Table IV, Eq. EF7).
For glucose media, the simulations revealed that S fbMMP2ATP
alone was not sufficient to describe total ATP generated from
mitochondria (OXPHOS) and cytosol (glycolysis). The altered
ATP production rates with low dose rotenone or FCCP
produced simulated ATP levels in excess of those reported.
As such, introduced into MITOsym was a second signal,
SEff glycolysis , which reduces the cellular pyruvate-to-ATP ratio
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when glycolysis signals are up-regulated.








The coefficient, K, was first adjusted to simulate ATP levels
consistent with those measured in HepG2 cells treated with
low dose rotenone and FCCP while cultured in 25 mM glu-
cose. K was subsequently refined by simultaneously adjusting
it in concert with S fbMMP2ATP to generate simulated ATP levels
across the full dose range for both mitochondrial effectors. It
was assumed that ATP utilization was consistent in all exper-
imental settings.
RESULTS
Effects of Media Glucose Concentrations on OCR
and ECAR
Effects of media glucose concentrations on oxygen consump-
tion rates (OCR) and extracellular acidification rates (ECAR)
were investigated in this study. OCR and the ECAR of
HepG2 cells were measured in real-time, simultaneously, in
an extracellular flux analyzer (Seahorse Bioscience, Billerica,
MA) with various concentrations of glucose. The reserve
capacity of the cells was measured by the addition of 3 μM
FCCP, and the OCR and ECAR immediately prior to FCCP
injection were used as the basal OCR and ECAR, respectively
(see Method section for more details). In these experiments,
OCR and ECAR both changed as media glucose concentra-
tions increased from 0 to 25 mM (Figs. 2 and 3). OCR was
highest when cells were cultured in 0 mM glucose and de-
creased towards a plateau as media glucose levels reached
5 mM; the plateau OCR was 2.5 fold lower than the value at
0 mM media glucose. In contrast, ECAR increased with
glucose concentrations. The spare respiratory capacity follow-
ing the administration of 3 μM FCCP increased with glucose
levels and reached a plateau at 5 mM (Fig. 3).
These results were used to guide dynamics of glucose
uptake and utilization in MITOsym as described in the
Methods section. Low glucose media decreased G6P produc-
tion rate (Fluxprod
G6P) which activated a feedback signal (S fbG6P2Glu )
(Table V) to increase the flux of glucose 6 phosphate (Eff_
Fluxprod
G6P). At 1 mM glucose, the modulated glycolysis flux (Eff_
Fluxprod, cellular
pyr ) is still lower than the flux estimated for 5 mM
glucose. However, there was only a slight reduction in mito-
chondrial proton gradient and mitochondrial ATP produc-
tion by the increased mitochondrial signal: S fbmitoPyr , S fbmitoOX
and SfbH Gradient (Table V). The simulated OCR and ECAR
profiles with increasing media glucose concentrations were
similar to the measured data, as illustrated by the similarity
in simulated and measured OCR/ECAR ratios (Fig. 4a). The
simulated dose–response relationship between media glucose
and respiratory capacity was also comparable with the mea-
sured data (Fig. 4b), showing an increase as glucose concen-
trations increased to a plateau when glucose≥2 mM.
Simulation of Mechanism-Based Mitochondrial
Responses to Specific Compounds
Mechanism-specific disruptions of mitochondrial function
were evaluated with three classic mitochondrial compounds
in MITOsym. Rotenone was used to investigate the mito-
chondrial response to direct ETC complex I inhibition. FCCP
was used to test respiratory capacity when compensating for
the uncoupling of the proton gradient. Oligomycin was used
to evaluate the mitochondrial response to inhibition of the
F1FO - ATPase. To examine the mechanism-specific effect of
the exemplar compounds (rotenone, FCCP, and oligomycin),
cellular respiration (OCR) and glycolysis (ECAR) were mea-
sured before and after addition of these compounds. The
OCR and ECAR immediately prior to the compound injec-
tion were used as the basal OCR and ECAR, respectively,
and were defined as 100% when generating the
concentration-response curves for each compound. OCR
and ECAR data for rotenone and FCCP(3) in addition to
new data for oligomycin effects on OCR and FCCP effects on
ΔΨm are listed in Appendix C and Figs. 5 and 6. FCCP,
rotenone, and oligomycin all display a clear dose–response
relationship for OCR and ECAR. However, the effects
on OCR are compound specific. OCR was increased by
400% when FCCP≥1 uM (Fig. 5b), while decreases in
OCR are observed for both rotenone (Minimum
Fig. 2 Measured basal OCR and ECAR response with increasing glucose
concentration in HepG2 cells (range 0–25 mM glucose). Note that the
displayed OCR and ECAR ratios were computed by normalizing by the
measured values by those collected from the 5 mM glucose experiments.
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OCR=20% of initial value) and oligomycin (Minimum
OCR=26% of initial value) (Fig. 6a, d). ECAR was
increased 150, 60 and 40% for 1 uM FCCP (Fig. 5c),
rotenone (Fig. 6b), and oligomycin (Fig. 6e), respective-
ly. Additionally, FCCP decreased the ΔΨm by 5% at
1 uM and by 65% at 3 uM (Fig. 5a).
These mechanism-specific data were used to construct a
homeostatic control network in MITOsym consisting of
various regulation signals (Fig. 1) to describe how the meta-
bolic pathways interact with each other. The simulated bio-
energetic outputs are the synchronized results of modulated
metabolic fluxes which account for single or multi-step signals.
Using FCCP as an example, the increased uncoupling
effects lead to reduced ΔΨm (Fig. 5a) and increases in
S fbH Gradient (Fig. 5d) and ETC activity (Fig. 5b). Increased
ETC activity reduced the mitochondrial oxidative substrate
Fig. 3 Measured spare respiratory
capacity in HepG2 cells exposed to
various media glucose
concentrations (range 0–25 mM
glucose). Cells were exposed to
3 uM FCCP at t=25 min. The
OCR values have been normalized
by the values collected prior to
FCCP exposure to compute the
OCR ratio.
Table V Bioenergetic Parameters and Properties Simulated in Various Conditions
Basal value (Glucose) Basal value (Galactose) Rotonone 0.5 uM FCCP 3 uM Oligomycin 1 uM
5.5 mM 1 mM
Intermediates
G6P [mM] 1.0 0.13 1.0 0.96 0.87 0.98
Pyruvatecellular [mM] 5.0 4.64 4.7 7.91 4.95 6.95
Pyruvatemito [mM] 5.0 4.89 4.7 8.12 4.11 6.70
ATPcellular [mM] 4.0 3.95 3.88 1.97 3.41 NA
ΔΨm 172.2 172.2 169.4 37.4 124.0 184.3
Calculated flux
Eff_Fluxprod
G6P [mM/min] 1.87 1.76 2.13 2.56 4.19 2.35
Eff_Fluxprod, cellular
pyr [mM/min] 3.75 3.53 4.26 5.18 8.38 4.69
Eff_Fluxprod
lac [mM/min] 3.15 2.92 3.45 4.98 5.96 4.38
Eff_Fluxprod, mito
pyr [mM/min] 0. 6 0. 6 0.84 0.19 2.42 0.31
Eff_Fluxprod
pyr2OX [mM/min] 0. 6 0. 6 0.84 0.19 2.42 0.31
Eff_Fluxprod
ETC [mM/min] 0. 6 0. 6 0.84 0.19 2.42 0.31
Eff_Fluxmito,lowgradient
ATP [pmol ATP/min] 1000 999.6 1334.7 259.7 711.1 NA
Eff_Fluxprod,gly
ATP [pmol ATP/min] 337.2 320.3 0 403.1 430.8 NA
Pathway signal (normalized)
SfbH Gradient 1 1.02 1.38 4.17 4.17 0.19
SfbG6P2Glu 1 3.40 1.14 1.38 2.24 1.24
SfbATP2gly 1 1 1.00 1.08 1.02 1.06
SfbETC2gly 1 1 1.15 1.28 2.21 1.19
SfbmitoPyr 1 1.07 1.19 0.23 1.8 0.42
SfbmitoOX 1 1.07 1 0.07 1 2.56
SfbMMP2ATP 1 1 0.97 0.88 0.92 1
SEff glycolysis 1 0.99 NA 0.89 0.63 1
Sfb_ATP2mitoATP_prod 1 1 1.4 1.18 1.05 1
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([Pyruvatemito]), and increased the flux of pyruvate entering
mitochondria through increased SfbmitoPyr (Fig. 5e). In parallel,
the decreased ΔΨm and increased ETC activity together up-
regulated glycolysis signals (Fig. 5f), which led to ECAR in-
creases (Fig. 5c). The simulated ΔΨm and OCR are compa-
rable with the measured data. However, the simulated ECAR
was underestimated. One thing to note is that the magnitude
of change in MITOsym relating the feedback signal for gly-
colysis (S fbmito2glycolysis ) (2.5X) was greater than the simulated
ECAR change (2.1X) (Fig. 5c vs. 6f). This is due to the fact that
simulated ECAR is computed only from lactate flux, while
glycolysis provides pyruvate for both lactate release and mito-
chondria pyruvate uptake.
The simulated OCR and ECAR outputs are also in agree-
ment with the measured data for rotenone and oligomycin
(Fig. 6). By design, a non-linear relationship between ETC
flux (hence, OCR) and ΔΨm are predicted for rotenone
(Fig. 6b). Our simulation results predicted an increase in
ΔΨm (Fig. 6e) for oligomycin (despite the decrease in OCR,
Fig. 6d) as a consequence of the increased ΔΨm eliciting a
decrease in the magnitude of the feedback signal S fbH Gradient .
The metabolic fluxes and the relative intermediate concen-
trations computed with MITOsym provide additional infor-
mation on the predicted integrated response to mitochondrial
effectors. Simulations with MITOsym indicate that 0.5 uM
rotenone would inhibit 70% of ETC activity in HepG2 (as
illustrated by OCR in Fig. 4a), cause the accumulation of
cellular and mitochondria pyruvate, a decrease in ΔΨm, and
an associated reduction of ATP (Table V). Moreover, these
changes elicited further alterations in the glycolysis flux (Eff-
Fluxprod, cellular
pyr , Table V), motivated by increases in the feedback signals,
(SfbETC2gly and SfbATP2gly ).
For 3 uM FCCP, the model predicted a 30% reduction of
ΔΨm, despite the 417% increased of ETC activity (Eff_Fluxprod
ETC)
relative to untreated values. The augmented ETC activity was
largely due to the effects of the feedback signal (S fbH Gradient ),
which increased substantially in response to the reduced ΔΨm
(Table V). The predicted response to 1 uM oligomycin included
an increase in ΔΨm, a 50% reduction in ETC activity, OCR,
and an accumulation of cellular and mitochondria pyruvate
(Table V). The reduced ETC activity was primarily the result
of two feedback signals, (S fbmitoOX and SfbH Gradient ).
Effects of Consecutive Administration of Mitochondria
Effectors on OCR
We next investigated whether MITOsym could simulate ef-
fects of consecutive administration of the mitochondria effec-
tors, oligomycin, FCCP, and rotenone onOCR. As illustrated
in Fig. 7, 1 uM of oligomycin, FCCP, and rotenone were
sequentially administered. The measured OCR decreased
50–70% in response to 1 μM oligomycin, increased to 20~
100% above basal levels after 1 μM FCCP, and decreased to
20–35% of basal after 1 μM rotenone, as reported previously
(9–11). This experimental protocol was simulated in
MITOsym (Fig. 7) using the same parameters as were used
to generate the response to each individual compound (Figs. 5
and 6). Therefore, these simulations serve as a validation of
the framework of MITOsym. The simulation results compare
well with the measured experimental data, given the amount
of reported variability using this experimental protocol.
Effects of Rotenone or FCCPon ATP levels in Simulated
HepG2 Cells Cultured in Glucose or Galactose
MITOsym was extended beyond simulations of respiration to
predictions of ATP levels in cultured HepG2 cells. The rela-
tive contributions to ATP from mitochondria and glycolysis
were captured in simulations of cells cultured in media con-
taining glucose or galactose, as galactose does not provide net
ATP synthesis via glycolysis. For these simulations, the model
settings were similar except for the net ATP production from
glycolysis is zero and mitochondria ATP production
(SEffMMP2ATP ) is less efficient for the galactose media condition.
For ATP estimation, ATP-dependent (1st order) reduction in
ATP utilization was employed; and an additional glycolysis-
ATP adjustment signal (SEff glycolysis ) was included for glucose
media (Table IV, EF8 and Table V). Moreover, media-
Fig. 4 Comparison of the
observed vs. simulated OCR/ECAR
ratio (left) and spare respiratory
capacity (right) in HepG2 cells
exposed to various levels of media
glucose (range 0–25 mM glucose).
Note that the dependent values
(Y-axis) are normalized by the values
reported or simulated at 5 mM
glucose condition.
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specific parameters to describe mitochondrial-ATP efficiency
(SEffMMP2ATP ) were determined based on comparison with
measured and published ATP data (2) as described in the
Methods section. Oligomycin-based changes to ATP levels
were not included in these simulations due to the data dispar-
ity (see Discussion).
Simulated ATP levels reached a new steady state in less than
2 h when cells switched from glucose to galactose media. The
Fig. 5 Comparison of the
simulated and measured OCR,
ECAR and mitochondria
membrane gradient and the
associated regulation signals.
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simulated basal, untreated ATP concentrations for glucose and
galactose media conditions are within 5% of each other
(Table V), a finding consistent with published ATP data. Simu-
lations of HepG2 cells cultured in galactose indicated that there
was a 40% increase of mitochondrial ATP synthesis (Sfb_
ATP2mitoATP_prod), a 13% increase in glycolysis flux (Eff_Fluxprod,-
cellular
pyr), and a 40% increase in ETC activity (Eff_Fluxprod
ETC)
(Table V) relative to simulations of HepG2 cells in glucose media.
There was good agreement between the simulated ATP
levels and the measured data across a dosing range of
rotenone and FCCP in HepG2 cells cultured in either
galactose or glucose media (Fig. 8). In the simulations of
HepG2 cells in glucose media, the pyruvate to ATP ratio
appeared to be reduced with increased glycolytic activity
(i.e., at higher rotenone or FCCP exposure). It is estimated
that contribution from glycolysis to ATP in simulations
with 0.5 uM rotenone and 3 uM FCCP is 40 and 38%
respectively, compared to 25% in the basal condition.
Moreover, with 3 uM FCCP, glycolysis (Eff_Fluxprod,cellular
pyr )
was predicted to increase 220% while the simulated
SEff glycolysis is 63% of baseline (Table V). The low ΔΨm
when HepG2 were exposed to 3 uM FCCP also likely
invoked the mitochondrial utilization of ATP. The simu-
lated net mitochondria ATP production rates (including
possible contributions from hydrolysis) were observed to be
lower in the galactose (77% reduction) vis a vis glucose
(8% reduction) media conditions. Overall, the good agree-
ment between the measured and simulated ATP concen-
trations confirms that MITOsym properly captures ATP
production and utilization dynamics.
Fig. 6 Simulation of OCR, ECAR
and mitochondria membrane
potential in response to rotenone
and oligomycin. Comparisons to
measured OCR and ECAR are also
included.
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DISCUSSION
Described herein is a mathematical model of hepatocellular
respiration and bioenergetics called MITOsym that has been
developed with the purpose of supporting drug screening
efforts towards reducing drug toxicity. Mitochondria-based
toxicity and dysfunction has been suggested to contribute to
the hepatotoxicity observed with multiple drugs. As such, cell-
based measurements of respiration using instruments such as
the Seahorse Biosciences XF analyzers (6) have been increas-
ingly used in the drug development process. MITOsym has
been designed to align with the OCR and ECAR measures
from these instruments in predicting hepatocellular changes in
ATP based on alterations in mitochondrial and glycolytic
function. This model includes mathematical representations
of the essential biochemical components of mitochondrial and
bioenergetic function, particularly in the in vitro, cultured
HepG2 cell environment. Data from experimental proce-
dures like those described in the examples herein, as well as
published data, can serve to calibrate the dynamics of these
interactions. Moreover, MITOsym has been designed to sup-
port predictions of in vivo hepatotoxicity in mice, rats, dogs,
and/or humans using DILIsym® (27).
The Dependence of HepG2 Bioenergetics on Media
Glucose
Glucose uptake and its contributions to bioenergetics ap-
pear to be cell-type or tissue-type dependent. We observed
a dependence of OCR and ECAR on media glucose
levels in HepG2 cells. In support of these results, Hue
et al. (30) reported increases in rat hepatocyte glycolysis
and lactate release in cells exposed to 0–50 mM media
glucose. Others have also reported a glucose dependency
for respiration in various tissues, including human islets
and porcine annulus fibrosus.
It appears that the saturation level for glucose concentra-
tions onHepG2 cell uptake, glycolysis, and cellular respiration
differs depending on themetabolic state of the cell. Our results
indicate that plateau OCR and ECAR levels were achieved
at≥3 mM media glucose when the HepG2 cells were in their
basal state. Upon the introduction of substantial levels of
FCCP and its increased respiratory burden due to the
uncoupling effects, the plateau OCR was observed
at≥5 mM media glucose. It is likely that the increases in
respiration when mitochondria are uncoupled require a
higher level of oxidative substrate than is needed in the basal
state. MITOsym captures the dose-dependency of media
glucose on OCR and ECAR in both the basal and the
uncoupled states in HepG2 cells (Fig. 4).
The Dynamics and Regulation of Mitochondrial
Membrane Potential and Respiration
Mitochondria are able to adjust ETC activity to accommo-
date changes to the mitochondrial membrane potential. We
observed a reduction in ΔΨmwhen HepG2 were treated with
≥1 μM FCCP, yet Nadanaciva et al. (2012)(3) reported OCR
increases at ≥0.1 μM (Fig. 5). The increased OCR is due to an
adaptive increase in ETC flux in an attempt to preserve ΔΨm
in the presence of the uncoupling effect of FCCP. The loss of
ΔΨm at ≥1 μM FCCP is likely due to inadequate provision of
substrate to sustain the increase in ETC activity. Others have
reported substantial reductions in ΔΨm in the presence of
≥1 μM FCCP (23,31) and increases in respiration ≥0.1 μM
FCCP (31).
The OCR reduction we observed when HepG2 cells were
treated with increasing concentrations of oligomycin
(Fig. 6d–f) is also likely linked to changes in ΔΨm. While
not measured in our study, oligomycin has been previously
shown to increase ΔΨm in rat hepatocytes (22,24), and this
is thought to be due to mitochondria F1FO -ATPase inhi-
bition and associated reductions in proton uptake (32).
Reduced proton flux likely reduces ETC complex activity
as well, providing a rationale for our observed dose-related
OCR decreases. The degree of OCR reductions is consis-
tent with what has been reported previously.
We captured this bidirectional relationship between ΔΨm
and ETC activity (as measured by OCR) in MITOsym. The
ΔΨm and OCR data from the experiments with FCCP and
oligomycin were used to help quantify this relationship and
identify the appropriate parameter values. A decrease inΔΨm
generated a signal (S fbH Gradient ) that increases ETC activity; the
magnitude of this signal was based on the FCCP data (Fig. 5).
Conversely, S fbH Gradient decreases ETC activity as ΔΨm
Fig. 7 Comparison of the simulated time-series OCR results with data
reported by three independent studies in HepG2 cells following a “stress-
test” protocol (1 μM of oligomycin, FCCP, and rotenone, added sequentially)
(Ferrick et al., 2008)
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increases. Oligomycin data were used to calibrate the signal
for this purpose. One thing to note is that we observed a
decrease in ΔΨm at higher oligomycin concentrations (or
longer incubation times) in our laboratory (data not shown).
Descriptions of this inverse oligomycin-gradient relationship
at higher doses could be included in the MITOsym in the
future. However, simulations revealed that S fbH Gradient alone
was not sufficient to accurately capture the ΔΨm and ETC
activity relationship. As such, we introduced a second signal,
S fbmitoPyr , which captured the feedback on mitochondrial sub-
strate uptake based on changes in ETC activity (Fig. 6e). The
rationale for this signal is that reductions in ETC activity (such
as with oligomycin or rotenone) would cause an accumulation
of oxidative substrate within mitochondria; this accumulation
of substrate would further influence mitochondrial uptake of
substrate. The combined signals work to restrict OCR when
FCCP is administered following oligomycin (Fig. 6) vs. when
FCCP is administered alone (Fig. 5). The difference is a result
of feedback from accumulation of mitochondrial oxidative
substrate (S fbmitoPyr ) due to oligomycin.
The Dynamics and Regulation of Glycolysis
It has been repeatedly observed that glycolysis rates increase
during times of mitochondrial duress (3,4,16). The in-
creased extra-mitochondrial ATP production via
glycolysis can offset the drug-induced decrement in mi-
tochondrial ATP production (2,4).
This dynamic interplay between mitochondrial impair-
ment and glycolysis rates has been included in MITOsym.
In MITOsym, glycolysis is described as the formation of G6P
and the subsequent conversion to pyruvate. Glycolysis has
been shown to be regulated by ATP levels (17), and ATP
was employed as the signal between mitochondria and glycol-
ysis in initial simulations. However, neither ATP concentra-
tions, ΔΨm, nor the rate of change of either were sufficient
descriptors for the activation of glycolysis in HepG2 cells
treated with FCCP, rotenone, or oligomycin. It is possible
that additional descriptions of metabolic intermediates such
as AMP or ADP could provide a better quantitative descrip-
tion for glycolysis as demonstrated in Schmitz et al. which used
AMP/ADP concentration and calcium-calmodulin-PFK
complex to explain the glycolysis regulation in muscle tissues
(33). In MITOsym, however, a more empirical approach was
used to derive the dynamic between glycolysis and mitochon-
drial oxidation. Glycolysis increases are regulated jointly by
changes of total ATP and ETC activity. Simulated ECAR
results are in good agreement with the measured data collect-
ed for rotenone and oligomycin (Fig. 6) but underestimates
ECAR values for FCCP (Fig. 5). The need for two signals to
regulate the link between mitochondrial function and glycol-
ysis is made apparent when comparing the response to FCCP
vs rotenone. With FCCP, there is a 150% increase in ECAR
Fig. 8 Comparison of the
measured versus the simulated
change in cellular ATP exposed to
FCCP or rotenone when HepG2
cells were cultured in media
containing galactose (10 mM) or
glucose (25 mM). (a) FCCP-ATP
dose response in galactose media;
(b)Rotenone-ATP dose response in
galactose media; (c)FCCP-ATP
dose response in glucose media;
(d)Rotenone-ATP dose response in
glucose media.
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while there is only a 10% reduction in ΔΨm (Fig. 5). A similar
ΔΨm reduction for rotenone elicits only a 10% ECAR in-
crease, however (Fig. 6).
Regulation of ATP
A critical index of mitochondrial dysfunction and risk for tissue
injury is cellular ATP concentrations. Both utilization and pro-
duction contribute to ATP levels. ATP utilization in MITOsym
is a concentration dependent, first-order process. Decreases in
ATP production are met with a reduction in ATP utilization,
acting to preserve cellular function and avoid ATP depletion and
the resultant necrosis (34). This modeling approach is consistent
with what has been described previously (14).
ATP production receives contributions from both mito-
chondrial OXPHOS and cytosolic glycolysis. Cells cultured
in media containing glucose receive contributions from both
pathways, while cells cultured in galactose only rely on mito-
chondrial ATP production (2,29,35). We utilized data from
HepG2 cells cultured in galactose- or glucose-containing me-
dia to establish the dynamics of mitochondrial ATP produc-
tion. Simulation results showed there were increases in mito-
chondrial ATP synthesis, glycolysis flux and ETC activity for
HepG2 cells cultured in galactose media (Table V). These
energy substrate-dependent changes are consistent with data
in various cells types (29,35,36).
The simulated changes in ATP levels withMITOsym were
generally consistent with the reported levels in HepG2 cells
treated with rotenone and FCCP in both galactose and glu-
cose media (2). For example, ATP levels were not fully deplet-
ed in the presence of large amounts of FCCP or rotenone in
simulations of HepG2 cells cultured in glucose media
(Fig. 8c,d); conversely, simulations with galactose media indi-
cated complete loss of ATP (Fig. 8a,b). Glycolysis was able to
partially preserve ATP levels despite the loss of mitochondrial
ATP production.
Close inspection of the dose–response curves for both
FCCP and rotenone indicate that the simulations overesti-
mate ATP levels at lower exposures relative to the measured
data. Using 1 μMFCCP as an example, the increases in OCR
and ECAR and the minor decrease in ΔΨm (Fig. 6) indicate
mitochondrial ATP production was preserved. Based on the
mitochondrial ATP production rates for the change in ΔΨm
(5% reduction) and the cytosolic ATP production rates based
on the measured ECAR (increased 100%), cellular ATP levels
were also predicted to be preserved in galactose media but
increased for glucose media. Marroquin et al.(2), however,
reported a 20 and 15% reduction in ATP in HepG2 cells
when cultured in galactose and glucose media with 1uM
FCCP respectively. It is possible that the mild uncoupling
elicited an increase in ATP utilization. It is also possible that
there are time-related differences, since OCR and ECAR are
measured within 2 h after FCCP treatment; while the ATP
levels were measured at 24 h.
Oligomycin inhibition of the F1FO - ATPase leads to
reductions of ATP levels, decreases in OCR, and increases
in ECAR (2,3). Interestingly, there are differences in the dose–
response relationships between oligomycin vs. ATP and
oligomycin vs. OCR. While MITOsym agrees well with both
OCR and ECAR measured data following oligomycin treat-
ment (Fig. 6) this is not the case with ATP levels (not shown).
OCR inhibition plateaus with approximately 1 μM
oligomycin in both simulations and measured data, but the
measured depletion of ATP after 24 h of treatment is appar-
ent with ≥0.01 μM oligomycin in HepG2 (2) and rat hepato-
cytes (34). We were unable to simulate similar reductions in
ATP inMITOsym when oligomycin concentrations were that
low (≥0.01 μM). Given the disparity in the measured
exposure-response relationships, we have elected to optimize
the oligomycin effects based on OCR and ECAR rather than
the ATP data. Future versions ofMITOsymmay include both
effects.
Comparisons with Previous Models of Mitochondrial
Function
Several previous reports of mathematical models of mitochon-
drial bioenergetics have been reported over time, including
very detailed, thermodynamic-based models of isolated mito-
chondria (37–39). MITOsym, however, is focused on simulat-
ing mitochondrial function and dysfunction in a cell-based
environment. MITOsym included essential biochemical com-
ponents of mitochondria and bioenergetic function and has
been designed to align with measurements of cellular respira-
tion (OCR) and glycolysis (ECAR). Thus, some of the bio-
chemical detail included in these previous models (e.g., TCA
cycle, calcium flux) has been excluded from MITOsym.
Hepatocyte modeling approaches similar to MITOsym
have been reported previously by Ainscow et al. for primary
rat hepatocytes and Dash et al. for skeletal muscle. With a
control analysis approach, Ainscow et al. (14) described the
control pattern between glycolysis, oxidative phosphorylation
and ATP consumption. Each factor influences its own flux as
well as the movement through the other metabolic blocks
including glycogen breakdown, NADH oxidation, and proton
leak (14). Dash et al. (40) investigated the regulation of meta-
bolic processes during exercise in skeletal muscle. Included in
this model are both glucose and fatty acid substrates, as
skeletal muscle can utilize either substrate in vivo. One ad-
vancement that MITOsym offers over these previous model-
ing efforts is the ability to simulate the integrated bioenergetic
response to multiple mitochondrial disruptors that have been
co-administered (i.e., oligomycin+FCCP+rotenone, Fig. 7).
MITOsym has several limitations that should be noted. It
does not currently include contributions from both glucose
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and fatty acids to mitochondrial ATP production.
MITOsym was designed to exclude fatty acids, consistent
with most HepG2 and hepatocyte experimental protocols.
Another limitation is that MITOsym does not discretely
represent different mitochondrial ETC enzyme complexes,
thereby limiting the ability to discern different ETC com-
plex inhibitors from one another. Another limitation is the
lack of published data indicating changes in cellular ATP
levels during the same time frame as OCR and ECAR
measurements (1–2 h after drug exposure). Rather, the
preponderance of the ATP data for HepG2 was available
after 24 h of exposure. Adaptations between 2 and 24 h
may explain some of the differences between simulated
ATP and measured data (Fig. 8). It should also be pointed
out that mitochondrial turnover or adaptive biogenesis is
not included, as these changes typically occur 24–48 h after
injury. Finally, the current version of MITOsym may not
accurately predict responses in primary hepatocytes due to
differences between hepatocytes and HepG2 cells. Future
versions of MITOsym will include some of the unique
metabolic characteristics of primary hepatocytes and enable
predictions of primary human and primary rat hepatocyte
responses. Additional advancements may be made to ad-
dress the other issues described here as well.
CONCLUSION
MITOsym helps support the evaluation of compounds in
drug development in several ways. The outputs have been
designed to align with specific measurements of mitochondrial
function using widely used laboratory instruments (e.g.,
Seahorse XF analyzers). The cell-based measurement of res-
piration (and the modeling thereof) includes extra-
mitochondrial adaptations. MITOsym includes several of the-
se adaptive elements, such as the increase in glycolysis (as
measured by ECAR) whenmitochondrial function is compro-
mised. MITOsym can also help with the interpretation of
OCR and ECAR data, as it requires specific mechanistic
elements to be defined when generating simulations of in vitro
experiments. These mechanistic hypotheses can be confirmed
when simulation results align with the measured data. More-
over, MITOsym can be used to identify compound-specific
mitochondrial dysfunction parameter values that can be sub-
sequently used in DILIsym® to predict in vivo hepatotoxicity
based on in vitro compound data (8).
While this is best applied to the evaluation of hepatotoxicity
in the version of MITOsym described in this report, it is also
possible that the model could be adapted to other cell types.
One such example could be adjusting the parameters to
represent mitochondria and cellular function in neurons to
support the development of treatments for Parkinson’s
disease. Recent findings implicate mitochondrial dysfunction
as a key molecular mechanism compromising dopamine neu-
ronal function and survival, and as an underlying cause of
pathogenesis in both sporadic and familial Parkinson’s disease.
It is our hope that MITOsym will indeed contribute to
reducing the incidence of DILI. In particular, we anticipate
that MITOsym can help reduce the resource burden associ-
ated with screening compounds for DILI risk. Simulations can
reduce the number of subsequent wet lab experiments and
potentially provide increased experimental focus. Also, as
described above, modeling can provide users with a greater
understanding of available data. MITOsym has been de-
signed to represent the dynamics associated with disruptions
in cell-based in vitro environments, and it will be partnered
with DILIsym® to translate these in vitro results to predictions
of in vivo hepatotoxicity risk in future studies.
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